SEARCH:      Monitor Keywords |  Custom RSS

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof October categorized by USPTO classification 10/09

20090259018 - Protein consentrate from starch containing grains: composition, method of making, and uses thereof: The present invention relates to methods of producing a protein concentrate from a starch containing grain and uses thereof. In an exemplary embodiment, the protein concentrate produced is used to prepare an aquaculture feed.... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office

20090259019 - Masp-2, a complement fixing enzyme, and uses for it: The invention relates to the discovery and characterization of mannan binding lectin-associated serine protease-2 (MASP-2), a new serine protease that acts in the MBLectin complement fixation pathway.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090259020 - Highly fluorinated beta-amino acids and methods of making and using same: wherein R1a and R1b are independently H, alkyl, F, or fluoroalkyl; wherein R2a, R2b, R2a′, and R2b′ are independently H, alkyl, F, fluoroalkyl, aryl, or alkenyl; wherein R3 is OH, alkoxyl, NH2, alkylamino, or dialkylamino; wherein R4a and R4b are independently H, alkyl, acyl, or alkyloxycarbonyl; wherein R11, R12, R13,... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090259021 - Liquid phase peptide synthesis of kl-4 pulmonary surfactant: The invention relates to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu4)4-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the α-carbon.... Agent: Philip S. Johnson Johnson & Johnson

20090259022 - Cdna encoding the human alpha2 delta4 calcium channel subunit: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the α2δ-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional α2δ-4 protein. The calcium channel α2δ-4 protein may be isolated for the purposes of binding experiments or... Agent: Philip S. Johnson Johnson & Johnson

20090259024 - Glucose dehydrogenase from aspergillus oryzae: The present invention effectively produces glucose dehydrogenase derived from Aspergillus oryzae, and provides more practical glucose dehydrogenase. The invention makes it possible to efficiently produce glucose dehydrogenase and to obtain glucose dehydrogenase in more practical manner by using a glucose dehydrogenase gene isolated from Aspergillus oryzae.... Agent: Leydig Voit & Mayer, Ltd

20090259025 - Lactoferrin: A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the... Agent: Fish & Richardson PC

20090259023 - Liquid buffered gdf-5 formulations: Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of... Agent: Philip S. Johnson Johnson & Johnson

20090259026 - Ligand: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090259027 - Human gm-csf antibodies: Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as... Agent: Fulbright & Jaworski, LLP

20090259028 - Prevention of leaching of ligands from affinity-based purification systems: In an affinity-type purification, ligands dissociated from the stationary phase that would otherwise leach into the species being purified are captured by a second ligand that is also incorporated into the stationary phase, the second ligand exhibiting an affinity-type interaction with the dissociated first ligand with sufficient specificity to avoid... Agent: Townsend And Townsend And Crew, LLP

20090259029 - [1, 2, 4] triazolo [1, 5-a] pyrimidine derivatives as chromatographic adsorbent for the selective adsorption of igg: and its corresponding enol-form, wherein X represents O, S, or NH; R1 represents H, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl, Ar, —C(O)NHR3, —C(O)—R3 or halo; R2 represents H, C1-3 alkyl or halo; R3 represents H, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl or Ar; n represents 0, 1, 2... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20090253894 - Method of polymyxin b recovery from fermentation broth: The invention is related to the method of polymyxine B recovery from fermentation broth for the purpose of pure substance recovery. The invention mentioned above is obtained by using the method of polymyxine B recovery from fermentation broth according invention, which abstract is characterized by, that the filtrate is obtained... Agent: Michael Best & Friedrich LLP

20090253895 - Printable materials: The present invention provides compounds of the general formula I, and uses thereof for printing electronic components such as wires, resistors and LEDs.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090253896 - Selective substrates for matrix metalloproteinases: The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the... Agent: Mcdermott, Will & Emery

20090253897 - Structural protein of adeno-associated virus with modified antigenicity, its production and its use: The present invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one modification which brings about a reduction in the antigenicity, its production and use.... Agent: Clark & Elbing LLP

20090253898 - Mathematical design of ion channel selectivity via inverse problem technology: Determining the structure of permanent charge for an ion channel formulates an abstract operator, describing ion channel parameters, comprising equations that are ill-posed. The model of ion channel behavior relates the function of the ion channel to the structure of permanent charge within the ion channel and concentrations ions around... Agent: Husch Blackwell Sanders, LLP Husch Blackwell Sanders LLP Welsh & Katz

20090253899 - Reconstituted polypeptides: The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods.... Agent: Viksnins Harris & Padys Pllp

20090253900 - Processing of peptides and proteins: The invention provides novel methionine aminopeptidase enzymes and their use.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090247731 - Boronic ester and acid compounds, synthesis and uses: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.... Agent: Millennium Pharmaceuticals, Inc.

20090247732 - Synthesis of glycopeptides with superior pharmacokinetic properties: The present invention relates to novel glycopeptides having improved pharmacokinetic properties, improved stability, methods of preparing said novel glycopeptides, and methods to use said novel glycopeptides.... Agent: Catalyst Law Group, Apc

20090247733 - Novel bone mineralization proteins, dna, vectors, expression systems: The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic... Agent: Medtronic Attn: Noreen Johnson - Ip Legal Department

20090247734 - Chemically derivatized cd4 and uses thereof: This invention provides two soluble polypeptides which comprise a portion of CD4 comprising all HIV gp120-binding epitopes present on intact CD4, wherein the polypeptide has a cysteine substitution at a residue which, in intact CD4, interfaces with HIV gp120. This invention also provides a method for making a derivatized soluble... Agent: Cooper & Dunham, LLP

20090247735 - Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers: This invention relates to the use of mixed mode chromatography for purification of a protein from a mixture containing other materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such a method into a multi-step procedure with other... Agent: Townsend And Townsend And Crew, LLP